Milestone Pharmaceuticals (MIST) Retained Earnings (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Retained Earnings for 9 consecutive years, with -$485.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 20.93% year-over-year to -$485.3 million; the trailing twelve-month figure through Jun 2026 stood at -$485.3 million (down 20.93% YoY), and the FY2025 full-year result was -$430.6 million, down 17.16% from the prior year.
• Retained Earnings eased to -$485.3 million in Q2 2026 per MIST's latest filing, from -$456.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$220.3 million in Q1 2022 and bottomed at -$485.3 million in Q2 2026.
• Historically, Retained Earnings has averaged -$342.9 million across 5 years, with a median of -$341.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings tumbled 35.27% in 2022, then dropped 12.73% in 2024.
• Over 5 years, Retained Earnings stood at -$266.3 million in 2022, then slipped by 22.41% to -$326.0 million in 2023, then declined by 12.73% to -$367.5 million in 2024, then dropped by 17.16% to -$430.6 million in 2025, then retreated by 12.7% to -$485.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$485.3 million, -$456.7 million, and -$430.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.